日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy

按二线治疗分层,分析接受阿特珠单抗/贝伐珠单抗治疗的肝细胞癌患者的特征和预后

Singal, Amit G; Özgürdal, Kirhan; Vassilev, Zdravko; Pisa, Federica; John, William S; Miller, Taavy A; Pathak, Prathamesh; Gordon, Sarah; Feinberg, Bruce; Pan, Xiaoyun

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

瑞戈非尼治疗肝细胞癌的真实世界实践(REFINE):一项前瞻性观察研究

Kim, Yoon Jun; Merle, Philippe; Finn, Richard S; Kudo, Masatoshi; Klümpen, Heinz-Josef; Lim, Ho Yeong; Ikeda, Masafumi; Granito, Alessandro; Masi, Gianluca; Gerolami, René; Cho, Sung Bum; Hsu, Chih-Hung; Huang, Yi-Hsiang; Jeng, Long-Bin; Kim, Do Young; Lin, Shi-Ming; Pinter, Matthias; Shao, Guoliang; Kato, Naoya; Kurosaki, Masayuki; Numata, Kazushi; Kuo, Kung-Kai; Mao, Yilei; Lin, Yih-Jyh; Zhu, Kangshun; Twumasi-Ankrah, Philip; Khan, Javeed; Awan, Maria; Ozgurdal, Kirhan; Qin, Shukui

Birt-Hogg-Dubé syndrome with novel FLCN gene mutations and different clinical presentations: Case series

伴有新型FLCN基因突变和不同临床表现的Birt-Hogg-Dubé综合征:病例系列

Erinç, Ayşegül; Azakli, Damla; Kirhan, Gülsüm; Satici, Celal

P-039. Serum prolidase could be a marker for fibrosis/cirrhosis?

P-039. 血清脯氨酸酶可能是纤维化/肝硬化的标志物吗?

Ozkan, Aybars; Ozaydin, Ismet; Kaya, Murat; Kucuk, Adem; Katranci, Ali Osman; Aydin, Ferzan; Uyanikoglu, Ahmet; Cindoğlu, Çiğdem; Kirhan, Idris; Yenice, Necati

The influence of schizotypal traits on attention under high perceptual load

分裂型人格特质对高感知负荷下注意力的影响

Stotesbury, Hanne; Gaigg, Sebastian B; Kirhan, Saim; Haenschel, Corinna